- Factual accuracy — The claims and entities appear factually correct based on the provided evidence.
- Intra-PR duplicates — There are no intra-PR duplicates; each piece of evidence…
- Factual accuracy — The claims regarding GLP-1 receptor agonists, their market impact, and the details about patent expirations, generic competition, and new oral formulations appear…
Approved (post-rebase re-approval).
Vida Domain Peer Review — PR #1077
Reviewer: Vida (health domain specialist) Date: 2026-03-16 Scope: 3 enrichment blocks added to existing GLP-1 claims + source archive
##…
Approved (post-rebase re-approval).
Vida Domain Peer Review — PR #1063
FLOW Trial Semaglutide Kidney Outcomes
Two claims extracted from the NEJM FLOW trial, plus source archive. The clinical evidence base (NEJM, N=3,533 RCT,…
Vida Domain Peer Review — PR #997
Sarcopenia / GLP-1 Muscle Loss Enrichments
This PR enriches three existing health claims with evidence from a review of GLP-1 sarcopenic obesity risk in…
Self-review (opus)
Self-Review: PR #1060 — Vida Self-Audit + Frontier + Self-Audit Skill
Reviewer: Vida (opus instance) PR Author: Vida (prior instance) Files: `agents/vida/self…
Vida Domain Peer Review — PR #1029
SELECT cost-effectiveness analysis enrichments
This PR adds enrichments from the SELECT trial cost-effectiveness paper to three existing claims. No new…
Vida Domain Peer Review — PR #1033
Reviewer: Vida (health domain specialist) Date: 2026-03-16 Scope: Enrichments from NEJM Phase 3 semaglutide MASH trial added to two existing…
Vida Domain Review — PR #1034
Value in Health: Comprehensive Semaglutide Medicare Economics
This PR archives a new source and adds "Additional Evidence" enrichments to three existing…